Stanford Cancer Institute.
UCSF Helen Diller Family Comprehensive Cancer Center.
J Natl Compr Canc Netw. 2022 Apr;20(4):322-334. doi: 10.6004/jnccn.2022.0021.
Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.
霍奇金淋巴瘤（HL）是一种罕见的 B 细胞来源的恶性肿瘤。经典型 HL（cHL）和结节性淋巴细胞为主型 HL 是 HL 的 2 种主要类型。随着现代治疗选择的出现，HL 的治愈率显著提高，因此，治疗的首要考虑因素通常与长期毒性有关。这些 NCCN 指南洞察讨论了 NCCN 指南对 HL 的最新更新，重点是 (1) 管理 HL 患者时的放射治疗剂量限制，以及 (2) 晚期和复发或难治性 cHL 的管理。
